利用CHAC1的mRNA表达开发一种用于乳腺癌患者的新型预后评分系统。
Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1.
作者信息
Jahn Beate, Arvandi Marjan, Rochau Ursula, Fiegl Heidi, Goebel Georg, Marth Christian, Siebert Uwe
机构信息
Institute of Public Health, Medical Decision Making & Health Technology Assessment, Department of Public Health, Health Services Research & Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics & Technology, Hall in Tirol, Austria.
ONCOTYROL, Division of Health Technology Assessment & Bioinformatics, ONCOTYROL - Center for Personalized Cancer Medicine, Innsbruck, Austria.
出版信息
J Comp Eff Res. 2017 Oct;6(7):563-574. doi: 10.2217/cer-2017-0015. Epub 2017 Sep 19.
AIM
To develop a prognostic score for primary breast cancer patients integrating conventional predictors and the novel biomarker CHAC1 to aid adjuvant chemotherapy decisions.
PATIENTS & METHODS: A prognostic score for overall survival was developed using: conventional predictors from a dataset of 1777 patients and the weight of CHAC1 mRNA expression from an independent dataset of 106 patients using multivariate Cox regression.
RESULTS
The new score includes: CHAC1 mRNA expression, age, tumor size, HER2 neu status, lymph node status and degree of malignancy. Using a cut-off value of 11 score points, 10-year survival was 82% in low-risk (n = 34) and 43% in high-risk patients (n = 72). The addition of CHAC1 resulted in 16% reclassification.
CONCLUSION
Including CHAC1 in prognostic prediction may aid (and change) personalized treatment selection.
目的
开发一种用于原发性乳腺癌患者的预后评分系统，整合传统预测指标和新型生物标志物CHAC1，以辅助辅助化疗决策。
患者与方法
使用多变量Cox回归，基于1777例患者数据集中的传统预测指标以及106例患者独立数据集中CHAC1 mRNA表达的权重，制定总生存预后评分。
结果
新的评分包括：CHAC1 mRNA表达、年龄、肿瘤大小、HER2 neu状态、淋巴结状态和恶性程度。采用11分的临界值，低风险患者（n = 34）的10年生存率为82%，高风险患者（n = 72）为43%。加入CHAC1后，重新分类的比例为16%。
结论
将CHAC1纳入预后预测可能有助于（并改变）个性化治疗选择。
Zotero 插件